The Biden administration on Tuesday announced the first ten drugs that will be negotiated with Medicare for price. This has launched a groundbreaking program that is expected to reduce government drug spending, but is being challenged in court by the pharmaceutical industry.
The drugs on the list are taken by millions of older Americans and cost Medicare billions of dollars annually. The drugs are selected by the Centers for Medicare & Medicaid Services through a process that prioritizes those that account for the highest Medicare spending, have been on the market for years, and are not yet facing competition from rivals.
Drugs selected for price negotiations
1. Eliquisfor preventing strokes and blood clots, from Bristol Myers Squibb and Pfizer
2. jardianfor type 2 diabetes and heart failure, by Boehringer Ingelheim and Eli Lilly
3. Xarelto, for preventing strokes and blood clots, from Johnson & Johnson
4. Januviafor type 2 diabetes, from Merck
5. Farxigafor chronic kidney disease, from AstraZeneca
6. Entrestofor heart failure, from Novartis
7. Enbrelfor arthritis and other autoimmune diseases, from Amgen
8. Ibruvicafor blood cancer, from AbbVie and Johnson & Johnson
9. Stelarafor Crohn’s disease, from Johnson & Johnson
10. Fiasp And NovoLog insulin products, for diabetes, from Novo Nordisk
